1652.Hk

1652.HK has a liquidity position that is below the typical threshold for financial health, with a current ratio of 0.56, indicating that the company's current assets are insufficient to cover its current liabilities. The company's cash and equivalents amount to 83.84 million CNY, which is less than its long-term debt of 301.23 million CNY, resulting in a negative net cash position. This suggests a potential liquidity risk, as the company may struggle to meet short-term obligations without additional financing or operational improvements.

The company's profitability is currently negative, with a net income of -11.78 million CNY and an operating income of -1.72 million CNY. This performance is below the industry median for profitability metrics, indicating that the company is underperforming relative to its peers. The return on equity (ROE) is -3.28%, and the return on assets (ROA) is -0.93%, both of which are negative and suggest poor capital efficiency and asset utilization.

There is no detailed segment or geographic breakdown provided in the available data, so it is not possible to assess the company's exposure to specific markets or product lines. However, the lack of diversification could pose a risk if the company is heavily reliant on a single market or product, which is not uncommon in the pharmaceutical industry.

The company's growth trajectory is uncertain, as there are no specific numeric deltas provided for the current or next fiscal year. Given the negative net income and operating income, it is likely that the company is not experiencing positive growth at this time. Without clear indicators of future revenue increases or cost reductions, the company's ability to grow and improve its financial position remains questionable.

The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio is 0.84, which is relatively moderate but still suggests a significant level of leverage. The negative net cash position is a key flag, indicating that the company may need to raise additional capital or restructure its debt to maintain operations. There is no mention of dilution sources or recent equity issuance, so the potential for share dilution appears to be low at this time.

There are no recent events or filings mentioned in the available data, so it is not possible to assess the company's recent performance or strategic direction based on disclosed information. The absence of recent events may indicate a lack of significant developments or a conservative approach to public disclosure.